Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
3.680
+0.120 (3.37%)
At close: Aug 22, 2025, 4:00 PM
3.430
-0.250 (-6.79%)
After-hours: Aug 22, 2025, 5:57 PM EDT
Perspective Therapeutics Employees
As of December 31, 2024, Perspective Therapeutics had 140 total employees, including 138 full-time and 2 part-time employees. The number of employees increased by 21 or 17.65% compared to the previous year.
Employees
140
Change (1Y)
21
Growth (1Y)
17.65%
Revenue / Employee
$8,821
Profits / Employee
-$678,236
Market Cap
273.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 140 | 21 | 17.65% |
| Dec 31, 2023 | 119 | 53 | 80.30% |
| Jun 30, 2022 | 66 | 5 | 8.20% |
| Jun 30, 2021 | 61 | 8 | 15.09% |
| Jun 30, 2020 | 53 | 10 | 23.26% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CATX News
- 9 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results - GlobeNewsWire
- 20 days ago - Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
- 4 weeks ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025 - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting - GlobeNewsWire
- 3 months ago - Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - GlobeNewsWire